Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.
Nazareth T, Purser M, Bhaila R, Philbin M, Mladsi D. The economic burden of moderate-to-severe multiple sclerosis relapse in the United States: findings from a systematic literature review. Poster presented at the 69th AAN Annual Meeting; April 2017. Boston, MA. [abstract] Neurology. 2017 Apr 18; 88(16 Suppl).
Mladsi D, Ramamohan V, Ronquest N, Boklage SH. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among SIADH patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S33.
Ramamohan V, Mladsi D, Ronquest N, Boklage S. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among CHF patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S53.
Neighbors DM, Bell TJ, Wilson J, Dodd SL. Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manage. 2001 Feb 1;21(2):129-43. doi: 10.1016/s0885-3924(00)00247-5.
Neighbors DM, Dodd SL. Re: economic evaluation of fentanyl - Response. J Pain Symptom Manage. 2001 Jan 1;22(1):541-3.